Table 1 Demographic and clinical laboratory data of the study population
From: Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population
n (%) | |
|---|---|
Sex | |
Female | 132 (65.6) |
Male | 68 (34.4) |
Age | |
< 60 years old (mean) | 150 (75.1) |
≥ 60 years old (mean) | 50 (24.9) |
Diagnosis of Covid-19 | |
PCR | 20 (8.4) |
CT | 35 (18.0) |
Serology | 55 (27.0) |
PCR + CT + SEROL | 29 (15.3) |
PCR + CT | 14 (6.9) |
PCR + SEROL | 12 (6.9) |
CT + SEROL | 35 (17.5) |
Symptoms | |
Yes | 197 (98.5) |
No | 3 (1.5) |
Duration of symptoms | |
≤ 7 days | 58 (29.4) |
15 days | 69 (35.0) |
≥ 21 days | 70 (35.6) |
Hospitalization | |
Yes | 16 (8.0) |
No | 184 (92.0) |
Supplemental oxygen | |
Yes | 16 (8.0) |
No | 184 (92.0) |
Blood type (ABO) | |
A | 55 (27.5) |
B | 12 (6.0) |
AB | 5 (2.5) |
O | 89 (44.5) |
Unknown | 39 (19.5) |
H1N1 vaccine | |
Yes | 166 (83.0) |
No | 34 (17.0) |
BCG vaccine | |
Yes | 170 (85.0) |
No | 17 (8.5) |
Unknown | 13 (6.5) |
Pulmonary involvement | |
Normal | 9 (7.9) |
Mild (< 25%) | 75 (65.8) |
Moderate (25 to 50%) | 24 (21.0) |
Severe (> 50%) | 6 (5.3) |